Medical Bulletin 25/September/2023
Here are the top medical news of the day:
Mirabegron therapy does not prevent progression to Heart Failure: Study
Mirabegron therapy showed no significant impact on left ventricular mass or diastolic function over 12 months in patients with structural heart disease and no or mild heart failure symptoms, a recent study published in JAMA Cardiology has found.
Left ventricular hypertrophy (LVH) is a significant contributor to heart failure (HF) development and progression. For individuals in the pre-HF stage (stage B), there has been a lack of effective treatments to prevent the transition to overt HF (stage C). A new study investigated whether activating β3-adrenergic receptors (β3ARs) using the β3AR agonist mirabegron could be a safe and effective approach to prevent the progression of LVH and diastolic dysfunction in patients with pre- or mild HF.
Reference: Balligand J, Brito D, Brosteanu O, et al. Repurposing the β3-Adrenergic Receptor Agonist Mirabegron in Patients With Structural Cardiac Disease: The Beta3-LVH Phase 2b Randomized Clinical Trial. JAMA Cardiol. Published online September 20, 2023. DOI:10.1001/jamacardio.2023.3003
Waist-to-Hip Ratio (WHR) strongest predictor of mortality than BMI, Study finds
A recent study conducted on a large cohort of British individuals has revealed that the Waist-to-Hip Ratio (WHR) is a stronger and more consistent predictor of mortality compared to the Body Mass Index (BMI). The research emphasizes the importance of considering adiposity distribution, particularly WHR, in clinical assessments and recommendations.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.